ClinicalTrials.gg
RecruitingNCT07169591HCPGUpdated Oct 26, 2026

Postprandial Glucose Handing in Contraceptive and IUD Users

An observational study in Glucose Homeostasis, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by McMaster University · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 26, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
54
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 197 studies in Insulin Resistance with a site in Canada — 21 open to participants now, 27 under way, 4 of them phase 3. Insulin Resistance · Canada.

Planned enrollment
9th of 23
54 · median 30
Started
2025
with 8 others
Observational
23 of 197
3 open now
Primary completion
2027-07
later than 22 of 26 live
Registered
187th of 197
by date

Among the 197 studies in Insulin Resistance with a site in Canada, this one is the 9th largest by planned enrollment of the 23 observational ones that give a count, is one of 9 that started in 2025, is one of 23 observational ones, reaches primary completion later than 22 of the 26 other live ones, and was the 187th registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

21 of the 197 studies in Insulin Resistance with a site in Canada are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies in Insulin Resistance with a site in Canada, or all of them as a file.
02

Study summary

Goals: The long-term use of hormonal birth control has been shown to effect glucose handling, or blood sugar regulation, and potentially lead to insulin resistance which increases a person's risk for metabolic diseases such as type 2 diabetes. The goal of this study is to investigate how the body handles glucose, in three groups of young, healthy females: NAT (naturally cycling, or not using hormonal birth control), OCP (taking a birth control pill), and IUD (using an intrauterine device). Objectives: We will investigate if the body's ability to handle glucose differs between these groups. We will also explore if these differences are linked to the levels of primary sex hormones in females, estrogen and progesterone, and if the synthetic versions produced by hormonal birth control have the same negative effect. We will use an oral glucose tolerance test to investigate these potential differences, having participants drink a 75 gram glucose beverage and taking blood samples every 15-30 minutes for a 2-hour timespan. These blood samples will be used to measure glucose and insulin levels in the blood to determine any changes that occur in the body in response to glucose.

Read the detailed description

Insulin resistance is a common metabolic condition, and is considered a primary risk factor for the development of type 2 diabetes (T2D). As the prevalence of T2D continues to rise, particularly among premenopausal females (18-45 years), it is imperative to conduct additional research in this area. Fluctuations in primary sex hormones in females have been shown to modulate risk for developing impaired glucose tolerance, however, research in this area as well as work investigating synthetic versions of these hormones for OCP and IUD users remains unclear. It is crucial to investigate how hormonal contraceptives can alter glucose tolerance in young, otherwise healthy females, and what downstream effects contraceptives could have later in life.

03

Conditions studied

  • Glucose Homeostasis

Browse trials for

Keywords

  • Glucose
  • Insulin
  • Female Health
  • Hormonal Contraceptive
  • Intrauterine Device
  • Oral Contraceptive Pill
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We will recruit 54 young healthy recreationally active females (n=18 per group) 18-45 years of age from the following groups: 1) individuals currently taking second generation OCPs containing levonorgestrel, 2) individuals with a levonorgestrel-releasing IUD, and 3) NAT individuals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Within 18-45 years
  • between 18.5 and 30.0 kg/m2
  • Weight stable for the past 6 months (± 2kg)
  • VO2peak values within a below average to above average rangea
  • Fasting blood glucose \<6.0 mMb
  • Resting blood pressure \<140/90 mmHg

NAT females:

  • Regular menstrual cycle for > 6 months (defined as a cycle length of 21-35 days)

OCP users:

  • Use of combined OCPs as prescribed for > 3 months
  • Second generation levonorgestrel drugs only
  • Monophasic formulations only (Alesse, Alysena, Audrina, Aviane, Min-Ovral, Ovima, or Portia)

IUD users:

  • Insertion of IUD no fewer than 3 months prior to beginning of study
  • Hormonal, levonorgestrel-releasing IUD (Kyleena or Mirena)

Exclusion criteria

Exclusion Criteria:

  • Smoking
  • Diabetes, cancer, or other metabolic disorders
  • Cardiac or gastrointestinal problems
  • Infectious disease
  • Barium swallow or nuclear medicine scan in the previous 3 weeks
  • Pregnant or breastfeeding
  • Diagnosis of polycystic ovary syndrome
  • Endometriosis
  • Use of emergency (e.g., Plan B) within the previous 3 months

NAT females:

  • Use of any type of hormonal contraceptive in the previous 3 months

OCP users:

  • Not using OCP as prescribed (e.g. missing doses or taking drug inconsistently)
  • Use of OCP for longer than 3 years.

IUD users:

  • Insertion of Kyleena IUD longer than 2 years.
  • Insertion of Mirena IUD longer than 4 years.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
54 participants (estimated)
Patient registry
No

Groups and cohorts

  • NAT

    Naturally-cycling females

    Diagnostic Test: Oral Glucose Tolerance test (75g 2-hour)

  • OCP

    Combined oral contraceptive users

    Diagnostic Test: Oral Glucose Tolerance test (75g 2-hour)

  • IUD

    Hormonal intrauterine device users

    Diagnostic Test: Oral Glucose Tolerance test (75g 2-hour)

Interventions

  • Diagnostic testOral Glucose Tolerance test (75g 2-hour)

    Standard oral glucose tolerance test with blood draws every 15-30 minutes for a 2-hour span

06

What researchers measure

Primary outcomes

  1. Glucose tolerance

    A 2-hour oral glucose tolerance test will be performed in fasted individuals

    Time frame: 2 hours

Secondary outcomes

  1. Glucose and lipid metabolites

    Peak concentration of whole blood glucose

    Time frame: Timepoints: 0 minute, 15 minute, 30 minute, 45 minute, 60 minute, 90 minute, 120 minute

  2. Glucose and lipid metabolites

    Insulin

    Time frame: Timepoints: 0 minute, 15 minute, 30 minute, 45 minute, 60 minute, 90 minute, 120 minute

  3. Glucose and lipid metabolites

    C-peptide

    Time frame: Timepoints: 0 minute, 15 minute, 30 minute, 45 minute, 60 minute, 90 minute, 120 minute

  4. Glucose and lipid metabolites

    Concentration of total and high-density lipoprotein cholesterols

    Time frame: Fasting (0 min timepoint)

  5. Glucose and lipid metabolites

    Concentration of non-esterified fatty acids (NEFAs)

    Time frame: Fasting (0 min timepoint)

Other outcomes

  1. Hormone availability

    Concentration of 17b estradiol (endogenous estrogen)

    Time frame: Fasting (0 min timepoint)

  2. Hormone availability

    Concentration of endogenous progesterone

    Time frame: Fasting (0 min timepoint)

  3. Hormone availability

    Concentration of ethinyl estradiol (exogenous estrogen)

    Time frame: Fasting (0 min timepoint)

  4. Hormone availability

    Concentration of levonorgestrel (exogenous progesterone)

    Time frame: Fasting (0 min timepoint)

07

Study locations

1 of 1 sites recruiting
  • McMaster University, Ivor Wynne Centre
    Hamilton, Ontario L8S 4K1, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — To protect participant privacy, IPD will not be available to other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2025 (actual). Primary completion is estimated for Jul 2027, 21 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Jul 2026 → Jul 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Sep 12, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Jul 2027was Jul 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Jul 2027
Oct 26, 2026
Study completion
Oct 2026→Oct 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Jul 2026→Jul 2027
    Study completion Oct 2026→Oct 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07169591
Responsible party
Kirsten Bell (Principal Investigator, McMaster University) — Principal investigator
First posted
Sep 12, 2025
Start date
Oct 1, 2025
Primary completion
Jul 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Kirsten E Bell, Ph.D.
Contact
bellke3@mcmaster.ca
905-525-9140 ext. 24872

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion